News & Events about Atea Pharmaceuticals Inc.
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination statusBOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage ...
Ticker Report
2 months ago
Atea Pharmaceuticals (NASDAQ:AVIR Get Rating) had its target price reduced by JPMorgan Chase Co. from $12.00 to $8.00 in a report published on Thursday morning, Benzinga reports. They currently have a neutral rating on the stock. Several other equities research analysts also recently ...
Globe Newswire
2 months ago
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the 36th ...
Globe Newswire
4 months ago
Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination ...
Atea Pharmaceuticals (NASDAQ:AVIR Get Rating) had its price objective lowered by JPMorgan Chase & Co. from $10.00 to $8.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the stock. A number of other research analysts have also ...